Bloomberg News

Boehringer Has 25% of Its Research in Biotech, Sueddeutsche Says

March 27, 2012

A quarter of Boehringer Ingelheim GmbH (BING)’s research projects are based on biotechnology, Sueddeutsche Zeitung reported, citing an interview with Chief Executive Officer Andreas Barner.

The company is circumspect about acquisitions, Barner told the newspaper.

To contact the reporter on this story: Julie Cruz in Frankfurt via jcruz6@bloomberg.net

To contact the editor responsible for this story: Sara Marley at smarley1@bloomberg.net


Toyota's Hydrogen Man
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus